Skip Navigation

Johns Hopkins University

Sidney Kimmel Comprehensive Cancer Center
Weinberg Building, Room 1355
401 North Broadway
Baltimore, MD 21231-1146
(410) 955-8851
(866) 999-3345
http://www.hopkinskimmelcancercenter.org/index.cfm

Number of Transplants Performed

This center has been performing allogeneic transplants since 1969 and has been an NMDP transplant center since October 1997.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
52 2 1 --- 55
Unrelated Donor
- Pediatric
3 0 1 --- 4
Related Donor
- Adult
263 13 0 --- 276
Related Donor
- Pediatric
17 1 1 --- 19
Autologous
- Adult
--- --- --- 103 103
Autologous
- Pediatric
--- --- --- 8 8
Total
(by cell source)
335 16 3 111 465

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

Johns Hopkins Oncology Center


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2010, 2011 and 2012, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 468 patients.

The actual 1-year survival of these patients is 74.0%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 66.9% and 74.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

Johns Hopkins University - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- 2/2 1/2 2/2 5/7 4/7 3/3 17/23
Acute lymphoblastic leukemia in second complete remission 1/1 -- 0/1 -- 1/2 1/1 -- 3/5
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 0/1 1/1 -- 1/1 -- 2/3
Acute myelogenous leukemia in first complete remission -- 1/2 2/3 1/2 6/7 11/16 6/11 27/41
Acute myelogenous leukemia in second complete remission -- -- 2/2 2/2 5/6 6/7 3/6 18/23
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure 0/1 0/1 1/3 2/3 2/5 2/8 2/5 9/26
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 2/3 1/3 5/7 8/13
Chronic myelogenous leukemia in first chronic phase -- -- -- -- -- 1/1 -- 1/1
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- 1/1 1/1 -- -- -- -- 2/2
Chronic myelogenous leukemia in blastic phase -- -- -- -- 1/1 1/1 -- 2/2
Disorders of the immune system 2/2 -- -- -- -- -- -- 2/2
Histiocytic disorders -- -- 1/1 -- -- -- -- 1/1
Hodgkin lymphoma -- 1/1 5/6 5/5 3/3 4/6 1/1 19/22
Inherited abnormalities of erythrocyte differentiation or function 2/2 3/3 4/4 4/4 2/2 -- -- 15/15
Inherited disorders of metabolism -- -- 1/1 -- -- -- -- 1/1
Multiple myeloma / Plasma cell disorder -- -- -- -- 4/5 2/2 -- 6/7
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- -- -- 1/1 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- 2/2 2/2 3/4 7/8
Myelodysplastic disorders - Other MDS -- -- 0/1 -- -- 5/5 4/7 9/13
Myeloproliferative syndromes 1/1 -- -- -- -- 1/1 1/1 3/3
Non-Hodgkin lymphoma -- -- 2/3 2/3 11/13 25/31 28/40 68/90
Other acute leukemia -- -- 1/1 1/1 1/1 0/1 1/1 4/5
Severe aplastic anemia 1/1 3/3 2/2 1/1 1/1 2/2 -- 10/10
Solid tumors / Other malignancies 0/1 -- -- -- -- -- -- 0/1
Total 7/9 11/13 23/32 21/24 46/58 69/95 58/87 235/318

Johns Hopkins University - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission 1/1 -- 3/3 4/5 3/3 1/1 -- 12/13
Acute lymphoblastic leukemia in second complete remission -- 1/2 -- -- -- -- -- 1/2
Acute myelogenous leukemia in first complete remission 2/3 -- 1/1 4/4 1/2 2/4 3/5 13/19
Acute myelogenous leukemia in second complete remission -- 1/1 0/2 2/2 1/1 1/3 -- 5/9
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/1 1/1 1/3 -- 0/1 3/6
Chronic lymphocytic leukemia and other chronic leukemia -- -- 1/1 -- -- 1/2 -- 2/3
Chronic myelogenous leukemia in first chronic phase -- -- -- -- 1/1 -- -- 1/1
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- -- 3/5 -- -- 3/5
Histiocytic disorders 1/2 -- 1/1 -- -- -- -- 2/3
Inherited disorders of metabolism 1/1 -- -- -- -- -- -- 1/1
Multiple myeloma / Plasma cell disorder -- -- -- -- 1/1 1/1 -- 2/2
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- -- -- -- 1/1 -- 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- -- 1/1 -- 1/1
Myelodysplastic disorders - Other MDS 1/1 -- -- 1/1 2/2 2/3 -- 6/7
Myeloproliferative syndromes 1/1 -- -- -- -- 2/2 -- 3/3
Non-Hodgkin lymphoma -- 0/1 -- -- -- -- 2/3 2/4
Other acute leukemia -- 1/1 -- -- -- -- -- 1/1
Severe aplastic anemia -- -- 1/1 1/1 -- -- -- 2/2
Total 7/9 3/5 8/10 13/14 13/18 12/18 5/9 61/83

Program Description:

Johns Hopkins is a core center of the BMT clinical trials network; COG approved. Current studies are looking at ways to facilitate graft tolerance to reduce the risk of GVHD and reduce graft rejection in patients with mismatched donors, as well as investigating safer ways to transplant non-malignant diseases. Some patients with fully matched donors do not require immune suppression beyond four days after transplantation.

Contact Information:

If you have transplant-related questions, please contact Kim Drucis, transplant center coordinator, at (410) 502-0712 or by e-mail at kdrucis1@jhmi.edu.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

Richard Ambinder, Javier Bolanos-Meade, Ivan Borrello, Robert Brodsky, Amy Dezern, Ephraim Fuchs, Douglas Gladstone, Ivana Gojo, Carol Ann Huff, Richard Jones, Yvette Kasamon, Mark Levis, Leo Luznik, William Matsui, Jonathan Powell, Keith Pratz, B. Douglas Smith, Lode Swinnen

Pediatric -

Patrick Brown, Allen R. Chen, Kenneth Cohen, Kenneth Cooke, Alan Friedman, Christopher Gamper, David Loeb, Ido Paz-Priel, Margaret Showel, Donald Small, Heather Symons, Elias Zambidis

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Patrice McMullen by e-mail at mcmulpa@jhmi.edu or by phone at (410) 955-2549.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.